Realtime | Geld | Brief | Zeit |
---|---|---|---|
56,00 | 56,50 | 08:27 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | BMO Capital reiterates Outperform rating on Protagonist Therapeutics stock | 2 | Investing.com | ||
Di | Protagonist Therapeutics: Clear Street erhöht Kursziel nach Studiendaten deutlich auf 74 US-Dollar | - | Investing.com Deutsch | ||
Di | Protagonist Therapeutics stock price target raised to $74 at Clear Street | 1 | Investing.com | ||
Di | Protagonist Therapeutics: Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill | 187 | ACCESS Newswire | Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose... ► Artikel lesen | |
26.09. | Protagonist Therapeutics auf Rekordhoch: Aktie erreicht 66,7 US-Dollar | 4 | Investing.com Deutsch | ||
17.09. | Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews | 1 | Benzinga.com | ||
PROTAGONIST THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
17.09. | Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory | 2 | Insider Monkey | ||
17.09. | This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday | 2 | Benzinga.com | ||
17.09. | Protagonist Therapeutics: Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress | 198 | ACCESS Newswire | Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studiesIcotrokinra also showed sustained... ► Artikel lesen | |
15.09. | Protagonist Therapeutics: Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 | 276 | ACCESS Newswire | NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in... ► Artikel lesen | |
12.09. | This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday | 1 | Benzinga.com | ||
11.09. | Protagonist Therapeutics: Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency | 301 | ACCESS Newswire | Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints.... ► Artikel lesen | |
26.08. | Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 | 289 | ACCESS Newswire | NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer... ► Artikel lesen | |
25.08. | Protagonist Therapeutics: Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera | 335 | ACCESS Newswire | Breakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development programU.S. New Drug Application filing... ► Artikel lesen | |
07.08. | What 4 Analyst Ratings Have To Say About Protagonist Therapeutics | 2 | Benzinga.com | ||
07.08. | Protagonist Therapeutics stock price target raised to $69 by JMP | 1 | Investing.com | ||
06.08. | Protagonist Therapeutics, Inc - 10-Q, Quarterly Report | 3 | SEC Filings | ||
06.08. | Protagonist Therapeutics: Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 310 | ACCESS Newswire | NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in JulyANTHEM Phase 2b trial data of icotrokinra... ► Artikel lesen | |
06.08. | Protagonist Therapeutics, Inc - 8-K, Current Report | 4 | SEC Filings | ||
21.07. | Protagonist Therapeutics: Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis | 383 | ACCESS Newswire | Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptorFiling based on unprecedented data package that met all primary endpoints across four... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,90 | -0,60 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
EVOTEC | 6,630 | -3,01 % | NetraMark Holdings, Evotec, Sartorius - Milliardengeschäfte im Blick! | Künstliche Intelligenz und Maschinelles Lernen sind mittlerweile in fast allen Branchen wichtige Schrittmacher. Wenn Pharmaunternehmen ein Medikament bis zur Marktreife entwickelt haben, sprudeln die... ► Artikel lesen | |
BB BIOTECH | 41,800 | -0,83 % | EQS-News: BB BIOTECH AG: BB Biotech wird in den SPI ESG Index aufgenommen | EQS-News: BB BIOTECH AG
/ Schlagwort(e): ESG
BB Biotech wird in den SPI ESG Index aufgenommen
22.09.2025 / 07:00 CET/CEST
Für den Inhalt der Mitteilung ist der Emittent... ► Artikel lesen | |
MEDIGENE | 0,062 | -6,63 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
QIAGEN | 40,990 | +0,55 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
CUREVAC | 4,654 | -0,21 % | CureVac-Alarm: Insidern zufolge steht eine spektakuläre Trendwende bevor - handeln, bevor es zu spät ist!!! | ||
MODERNA | 24,315 | -2,99 % | MODERNA INC - Jetzt beginnt das Biotech-Comeback! | ||
PAION | 0,011 | 0,00 % | Interne Dokumente des Wirtschaftsministeriums zeigen: So lief der umstrittene Verkauf der Paion AG an chinesische Investoren ab | ||
AMGEN | 253,60 | +0,08 % | Amgen Launches AmgenNow, Direct-to-patient Program; Available To Repatha Patients | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha or evolucumab. Repatha will be available through AmgenNow at a... ► Artikel lesen | |
NOVAVAX | 7,774 | +1,51 % | Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU | ||
BIOGEN | 130,05 | +0,19 % | Erste Patienten bekommen Alzheimer-Mittel Lecanemab der Hersteller Biogen und Eisai | BERLIN (dpa-AFX) - Seit gut einem Monat ist das Alzheimer-Medikament Lecanemab der Hersteller Biogen und Eisai in Deutschland verfügbar - inzwischen haben erste Patientinnen und Patienten mit der Therapie... ► Artikel lesen | |
BIOFRONTERA | 2,680 | -2,90 % | Benchmark reiterates Buy rating on Biofrontera stock amid tariff concerns | ||
HEIDELBERG PHARMA | 3,040 | -2,56 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma gibt Aktualisierung der Prognose bekannt | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Prognoseänderung
Heidelberg Pharma AG gibt Aktualisierung der Prognose bekannt
06.10.2025 / 15:58 CET/CEST
Veröffentlichung einer... ► Artikel lesen | |
ILLUMINA | 83,58 | -0,61 % | ILMN Stock Set to Benefit From the Launch of New BioInsight Division | ||
CRISPR THERAPEUTICS | 66,50 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe | ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based... ► Artikel lesen |